Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 346

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 346
---
 party:

| Purchasers                                           |     | Pre-Funded Warrants Purchased |         |     | Total    
 Purchase 
 Price    |         |     | February 2025 Common Warrants Issued |         |
|:-----------------------------------------------------|:----|:------------------------------|--------:|:----|:---------|--------:|:----|:-------------------------------------|--------:|
| Atwood-Edminster Trust dtd 4-2-2000 and GVN, LLC (2) |     |                               | 510,200 |     | $        | 999,992 |     |                                      | 510,200 |

| (1) | Daniel Corey served as the Chief Technology Officer and a member of the board of directors of the Company from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February 2024. |

| (2) | Brian                                                                                                                                       
 G. Atwood served as Chairman and Chief Executive Officer of the Company from February 2024 to September 2024, and previously served as      
 Chairman of PBAX until the closing of the Business Combination in February 2024. Mr. Atwood is currently a member of the board of directors 
 of the Company and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000. GVN, LLC, is a limited liability company of which the        
 sole member is the Atwood-Edminster Trust dtd 4-2-2000, and of which Brian G. Atwood and Lynne H. Edminster are the managers.               |

| (3) | Chris                                                                                                                                   
 Ehrlich has served as the Chairman and Chief Executive Officer of the Company since December 2024, and previously served as (i) interim 
 Chairman and Chief Executive Officer of the Company from October 2024 to November 2024, (ii) Vice Chairman of the board of directors    
 of the Company from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until the closing of the Business    
 Combination in February 2024.                                                                                                           |

During the three months ended March 31, 2025 and
for the period from February 14, 2024 to March 31, 2024, the Company incurred a consulting fee of $ and $ to a member